Immune correlates of protection of the four-segmented Rift Valley fever virus candidate vaccine in mice

• Published in: Emerging microbes & infections 2024-12, Vol.13 (1), p.2373313
• Main Authors: Prajeeth, Chittappen K, Zdora, Isabel, Saletti, Giulietta, Friese, Julia, Gerlach, Thomas, Wilken, Lucas, Beicht, Jana, Kubinski, Mareike, Puff, Christina, Baumgärtner, Wolfgang, Kortekaas, Jeroen, Wichgers Schreur, Paul J, Osterhaus, Albert D M E, Rimmelzwaan, Guus F
• Format: Article
• Language: English
• Subjects: Animals; antibodies; Antibodies, Neutralizing - blood; Antibodies, Neutralizing - immunology; Antibodies, Viral - blood; Antibodies, Viral - immunology; Disease Models, Animal; Female; Immunity, Cellular; Immunity, Humoral; immunogenicity; Interferon-gamma - immunology; Mice; Mice, Inbred BALB C; Rift Valley Fever - immunology; Rift Valley Fever - prevention & control; Rift Valley fever virus - genetics; Rift Valley fever virus - immunology; RVFV; T cells; T-Lymphocytes - immunology; Vaccination; Vaccines; Vaccines, Attenuated - administration & dosage; Vaccines, Attenuated - immunology; Viral Vaccines - administration & dosage; Viral Vaccines - immunology
• ISSN: 2222-1751; 2222-1751
• DOI: 10.1080/22221751.2024.2373313

Rift Valley fever (RVF) is a mosquito-borne zoonotic disease caused by RVF virus (RVFV). RVFV infections in humans are usually asymptomatic or associated with mild febrile illness, although more severe cases of haemorrhagic disease and encephalitis with high mortality also occur. Currently, there are no licensed human vaccines available. The safety and efficacy of a genetically engineered four-segmented RVFV variant (hRVFV-4s) as a potential live-attenuated human vaccine has been tested successfully in mice, ruminants, and marmosets though the correlates of protection of this vaccine are still largely unknown. In the present study, we have assessed hRVFV-4s-induced humoral and cellular immunity in a mouse model of RVFV infection. Our results confirm that a single dose of hRVFV-4s is highly efficient in protecting naïve mice from developing severe disease following intraperitoneal challenge with a highly virulent RVFV strain and data show that virus neutralizing (VN) serum antibody titres in a prime-boost regimen are significantly higher compared to the single dose. Subsequently, VN antibodies from prime-boost-vaccinated recipients were shown to be protective when transferred to naïve mice. In addition, hRVFV-4s vaccination induced a significant virus-specific T cell response as shown by IFN-γ ELISpot assay, though these T cells did not provide significant protection upon passive transfer to naïve recipient mice. Collectively, this study highlights hRVFV-4s-induced VN antibodies as a major correlate of protection against lethal RVFV infection.